Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1412P - Palliative stents in a large cohort of advanced gastroesophageal cancers (GOC): Factors associated with long term survival

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Oesophageal Cancer;  Gastric Cancer

Presenters

Clare Hannon

Citation

Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708

Authors

C. Hannon1, B.H.R.D. Paula2, M. Goksu3, G. Corbett4, N. Carroll4, C.A.M.D. Sousa5, E. Smyth6

Author affiliations

  • 1 Oncology Dept., Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ - Cambridge/GB
  • 2 Oncology Dept., University of Cambridge, CB2 0SP - Cambridge/GB
  • 3 School Of Clinical Medicine, University of Cambridge School of Clinical Medicine, CB2 0SP - Cambridge/GB
  • 4 Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge/GB
  • 5 Dties/uerj, Rio de Janeiro State University (UERJ), Rio de Janeiro/BR
  • 6 Gastrointestinal Oncology Dept., Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ - Cambridge/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1412P

Background

Endoscopic stent placement is a common intervention to improve dysphagia in patients with GOC but post-procedural complications and prognosis post insertion have not been reliably described.

Methods

From an electronic medical record, patients with stent placement from 24/6/2015 to 30/3/2020 were identified. Demographic, clinical and outcome data were extracted. Significant post-stent adverse events (pain, bleeding, perforation, arrhythmia and refractory reflux/vomiting) were classified as acute (<7 days) or delayed (≥ 8 days). Overall survival (OS) was from stent placement to death or last follow up. Survival curves for relevant variables were compared using log-rank test and Kaplan Meier method.

Results

150 patients were identified: median age 76 years, 76% were male. Histology: 17% squamous, 76% adenocarcinoma and 7% other. Tumour site:10% gastric, 21% GOJ and 69% oesophageal cancer. Disease burden was metastatic in 44% and locally advanced in 56% of the patients. 43% patients received anticancer treatment before and 12% after stent; 19% had 2nd stent and 2% a 3rd one. 7% had an acute, 58% delayed and 1.3% severe complications (1 perforation and 1 arrhythmia). Median OS in the population was 3.4m (months) (2.8 – 3.9, CI 95%). Treatment post-stent was associated with a higher survival (10.2m, 7.1 – 13.3 CI 95%) than no treatment (3.0m, 2.3 – 3.7 CI 95%, p<001). Dysphagia improvement was also associated with improved survival (3.8m vs 2.5m, p=0.009) and immediate complications were associated with poor survival (1.7m vs 3.6m, p=0.008). Gender, tumour subtype, anatomical site, treatment pre-stent and delayed complications were not associated with survival. Patients who had a 2nd and 3rd stent placed had a higher survival than one stent, respectively (10.35m, 9.61 – 11.09 CI 95% vs 2.74m, 2.11 – 3.37 CI 95%, p<0.001) and (17.11m, 6.92 – 27.30 CI 95% vs 3.31m, 2.75 – 3.87 CI 95%, p=0.04).

Conclusions

Stent placement is a valuable treatment for patients with GOC dysphagia. Cancer treatment post-stent, dysphagia improvement and no acute complications are associated with better survival. Patients who require and who are fit for a second stent appear to have good survival, favouring a repeat stent placement in selected cases.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

E. Smyth: Non-Financial Interests, Institutional, Advisory Board, Travel: Astellas; Non-Financial Interests, Institutional, Advisory Board, Travel: AstraZeneca; Non-Financial Interests, Institutional, Advisory Board, Travel: BMS; Non-Financial Interests, Institutional, Advisory Board: Five Prime; Non-Financial Interests, Institutional, Advisory Board: Gritstone Therapeutics; Non-Financial Interests, Institutional, Advisory Board: Merck; Non-Financial Interests, Institutional, Advisory Board, Travel: Servier; Non-Financial Interests, Institutional, Advisory Board: Zymerworks. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.